Tuvusertib
- Generic Name
- Tuvusertib
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors
- Conditions
- Advanced Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT05687136
- Locations
- 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
- Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 123
- Registration Number
- NCT05396833
- Locations
- 🇺🇸
Providence Medical Foundation, Santa Rosa, California, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
🇺🇸Augusta University - formerly Georgia Regents University, Augusta, Georgia, United States
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
- Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 204
- Registration Number
- NCT04170153
- Locations
- 🇯🇵
National Cancer Center Hospital - Dept of Experimental Therapeutics, Chuo-ku, Japan
🇨🇳Beijing Cancer Hospital, Beijing, China
🇪🇸Hospital Universitari Vall d'Hebron - Oncology Dept., Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.